BioGaia ProTectis Baby Drops + D3, Probiotic in drops, 5ml

Vitamin D
With the recommended dosage of 5 drops per day, 400 IU of vitamin D is provided on the basis of the recommendations of the American Academy of Pediatrics (AAP) and the European Food Safety Authority (EFSA). Daily intake of 400IU of vitamin D is recommended as a dietary treatment for proper bone development in children.

Exclusively breastfed infants (for as long as breastfeeding lasts)
Premature infants (for the 1st year of life)

The probiotic L.reuteri Protectis®
The BioGaia® ProTectis + D3 drops contain L.reuteri Protectis®, the certified probiotic bacterium of the Swedish company BioGaia. Originally isolated from breast milk, it is one of the most studied probiotics in the world and the most studied in infants and children. Its safety and efficacy have been demonstrated in 108 clinical trials (last updated 12/2014).

L.reuteri Protectis® fully meets the requirements of the WHO. for probiotics. In an in vitro study comparing the viability of 35 different probiotic strains in a simulated human gastrointestinal tract over five days, it was shown that L. reuteri Protectis® was one of only three surviving strains. This fact was confirmed in vivo, when its intake by healthy people led to a significant colonization of the stomach, duodenum and ileum.

L. reuteri Protectis® colonizes the entire gastrointestinal tract, prevents the growth of harmful microorganisms, activates the immune system and improves gastrointestinal function.

Indicative clinical studies with probiotic L.reuteri Protectis®
In an open study published in the journal Pediatrics by Savino (2007) the effectiveness of L.reuteri Protectis® in relation to cimethicone was demonstrated:
74% reduced crying time with L. reuteri Protectis® compared with a
26% reduction in the administration of the chemical simethicone

In a study published in the journal Pediatrics by Savino (2010), the effectiveness of L.reuteri Protectis® in placebo administration was demonstrated:
74% reduced crying time with L. reuteri Protectis® compared to
38% reduction in placebo after from one week of treatment

A new, independent study published in the journal Pediatrics by Szajewska (2012) confirmed the effectiveness of L.reuteri Protectis® in relation to placebo administration:
75% success in treatment within two weeks with L. reuteri Protectis® compared with
18% in the placebo group
Significantly improved family quality of life in the L. reuteri Protectis® administration group
A new, independent study published in the journal JAMA Pediatrics by Indrio (2014) confirmed the possibility of preventing functional gastrointestinal disorders during the first trimester of life with administration of L.reuteri Protectis® in relation to placebo.

L.reuteri Protectis® in relation to placebo administration.